innovate advance engage educate
Maximized engagement. Maximized impact.
Paradigm Medical Communications delivers award-winning medical education designed to advance clinical knowledge and enhance patient care.
Through innovation, scientific rigor, and continuous refinement, we create evidence-based programs that engage diverse healthcare audiences and drive measurable outcomes and lasting impact.
CME Spotlight
Program Overview
View this engaging on-demand webinar, filmed live during 2025 Aesthetic Extenders Symposium (AES).
CME Spotlight
Program Overview
This activity features highly interactive modules addressing obesity science, evaluation, management, and strategies for positive discussions with patients and their care partners. Obesity pathophysiology and neurobiology are explored through a puzzle-based format. Learners can then apply assessment strategies using a case-based platform ranking clinical decisions based on guidelines, evidence, and best practices. A summary of obesity medications, with a deep dive into the safety and efficacy of glucagon-like peptide 1-based therapies, will be provided in an easy-to-navigate infographic. Supplemental videos exploring patient and care partner communication strategies surrounding obesity and its treatment options will complement the series.
In Collaboration With:
CME Spotlight
Program Overview
How do you manage new-onset exudative macular degeneration with subretinal hemorrhage and a large pigment epithelial detachment requiring prompt treatment? See what your approach would be in this case where you will review the case details and sort the management choices for the case into poor, better, and best practices. Your management choices are then compared with choices supported with a referenced rationale. In addition, expert clinical commentary is provided by Hani Salehi-Had, MD, FASRS, who reviews the case and presents his approach to managing this wet age-related macular degeneration (AMD) case requiring prompt treatment and follow-on care.
CME Spotlight
Common Practice Dilemmas in the Age of Second-Generation Therapy A Retina Unplugged Podcast Activity
Program Overview
Treatment paradigms are shifting with the advent of second-generation therapies (eg, faricimab and aflibercept 8 mg) for retinal vascular disease. How will this affect your practice? Listen to renowned experts as they share their own experiences with second-generation therapies and discuss related innovations, clinical challenges, and practical solutions (eg, optical coherence tomography monitoring, the role of biomarkers, and patient engagement) in this lively podcast activity.
CME Spotlight
Program Overview
Join this virtual case-based CME activity that explores IDH and FLT3 mutations and how they influence prognosis and guide targeted therapy decisions in patients with acute myeloid leukemia (AML). Our expert faculty will discuss clinical data supporting IDH1/2 inhibitors and FLT3-targeted agents and review treatment sequencing, resistance patterns, and integration of novel therapies into practice. The conversation will also take a deep dive into precision medicine and evidence-based care strategies to treat patients with AML who have these actionable mutations.
In Collaboration With:
CME Spotlight
Program Overview
In this Case Consults web activity, learners will review 2 case studies of patients with LN with insights from a nephrologist and a rheumatologist, including discussion of the latest guideline recommendations for the treatment of LN and the data informing the guideline recommendations. In addition, faculty discussion will focus on case-based clinical use incorporating new treatments for patients with LN and an overview of emerging treatments.
CME Spotlight
Program Overview
This dynamic CME program blends interactive case consultations with a data-driven deep dive into long-acting injectables (LAIs) for schizophrenia. Through engaging real-world scenarios, learners will explore barriers and biases that influence LAI utilization and discover communication strategies that foster shared decision-making with patients and caregivers. A comprehensive evidence review highlights innovative LAIs, their attributes, and the latest clinical trial findings, offering practical insights for treatment planning. This unique format equips clinicians with both the knowledge and the skills to optimize adherence, improve outcomes, and confidently integrate LAIs into patient care.
CME Spotlight
Program Overview
This interactive infographic will focus on the pathophysiology of Sjögren’s disease (SjD), supporting the rationale for the mechanisms of action of emerging targeted B-cell treatments in SjD and clinical data. This will include discussions of trial designs and outcomes measured, including impact on quality of life. The faculty discussions will reflect on treatment targets and highlight potential clinical applications of emerging agents.
This activity is jointly provided by Paradigm Medical Communications, LLC and Educational Review Systems, Inc.
In collaboration with Sjögren’s Foundation.
CME Spotlight
Program Overview
Join host Dr Sridhar and guests Drs Bakri and Ip for a podcast highlighting the challenges in care of patients with macular edema secondary to retinal vein occlusion (RVO). With the American Academy of Ophthalmology RVO Preferred Practice Pattern as a guide, the faculty consider the current approach to treatment using anti-vascular endothelial growth factor (VEGF) agents and factors that may suggest a need for more intensive, long-term treatment. The anti-VEGF agents have been standard of care for over a decade; however, many patients need frequent injections to be effective. The anti-VEGF agents faricimab and aflibercept 8 mg have shown noninferior efficacy and greater durability in pivotal clinical trials at reducing patient treatment burden.
CME Spotlight
Program Overview
Sustained delivery innovations have the potential to transform the retinal landscape by significantly reducing treatment burden. For optimal outcomes, appropriate patient selection and careful administration are key. Stay ahead of the curve with this expert-led symposium that will bring sustained delivery advances to life. This comprehensive, expert-led curriculum blends real-life cases, video demonstrations, animations, and key data to inform evolving best practices in this dynamic field.
CME Spotlight
The Many Faces of Neovascular Retinal Disease: Individualizing the Use of Sustained Delivery Therapy
Program Overview
Join us for a dynamic CME activity exploring the future of retinal disease management. Discover how the ranibizumab port delivery system (PDS) and other therapies—such as tyrosine kinase inhibitors and gene therapies—are transforming treatment options and patient outcomes. Learn to identify ideal candidates, navigate updated drug indications, and optimize monitoring strategies. Through a fast-paced lightning round format, this program equips retina specialists and ophthalmologists with practical insights to confidently integrate innovative therapies into clinical practice. Don’t miss this opportunity to stay ahead in retinal care and improve patient satisfaction.
CME Spotlight
Program Overview
New treatment options such as anti-vascular endothelial growth factor (VEGF) therapies and advances in imaging technologies have changed the standard of care for retinal vein occlusion (RVO). What anti-VEGF agents are recommended as first-line therapy for RVO? Are the anti-VEGF agents successful in treating macular edema secondary to RVO?
Join Dr Katherine Talcott as she discusses the most up-to-date facts about who is diagnosed with RVO and what options are recommended by the American Academy of Ophthalmology Preferred Practice Pattern to treat macular edema secondary to RVO.
CME Spotlight
Program Overview
With the addition of aflibercept 8 mg and faricimab, ophthalmologists now have many options including biosimilars for intravitreal anti-vascular endothelial growth factor (VEGF) agents to treat diabetic retinopathy (DR) and diabetic macular edema (DME). How are you deciding which option to start with when initiating an intravitreal anti-VEGF therapy in your patient with center-involved DME? What factors are guiding your clinical decisions? Join Drs Do and Boyer as they discuss the intravitreal anti-VEGF treatment options and what factors they consider when recommending a particular agent to a patient.
CME Spotlight
Program Overview
Despite an expanding array of advanced therapies for IBD, many patients with moderate to severe disease remain refractory to current options. Anti- tumor necrosis factor-like ligand 1A (TL1A) agents represent a promising new class targeting TL1A, a cytokine implicated in IBD pathogenesis. Experts review the current landscape and contextualize emerging data that suggest TL1A blockade may deliver meaningful clinical outcomes. As late-phase trials progress, clinicians should stay informed on this novel mechanism of action and its potential role in personalized treatment strategies for IBD.
CME Spotlight
Register Now for Complimentary Live Virtual Meeting!
Wednesday, February 18, 2026
8:00 PM – 8:45 PM (EST)
5:00 PM – 5:45 PM (PST)
Program Overview
Despite the proven efficacy of intrauterine devices (IUDs), their use remains below 10%. Barriers include limited clinician knowledge on recommending IUDs and managing pain associated with lUD placement. Patients often experience pain that is underestimated, leading to dissatisfaction and discontinuation. Updated guidelines now recommend local anesthetics, including paracervical block, to reduce pain during insertion. However, most clinicians lack training in this technique and rely on nonsteroidal anti-inflammatory drugs, which lack evidence of effectiveness.
This CME program addresses these gaps by educating clinicians on pain management strategies and demonstrating paracervical block technique to improve patients’ experiences and outcomes.
Our Educational Design Process Puts Us Ahead
Practice gaps, educational needs, target audiences, desired outcomes.
Learning objectives, educational formats, timely content, assessment strategies.
Tailored learning plans to put education into action.
Feedback and data from multiple sources throughout the life cycle of the initiative.
Recognized By
Throughout its more than 20-year history of providing quality continuing education for healthcare professionals, Paradigm has been the proud recipient of numerous awards from various professional organizations concerned with innovation and improvement in the CME field.
